TRP_1170x120_3-8-19

Joseph Agnese

Outlook: New landscape for drug chains?

Outlook: New landscape for drug chains?

NEW YORK — Entering the second quarter of 2017, the chain drug industry was awaiting answers to a couple of big, lingering questions. First, what will the chain drug landscape look like? A significant change in the field of players is likely in store pending antitrust clearance of Walgreens Boots Alliance Inc.’s (WBA’s) deal to

Outlook: Transition time for drug chains

Outlook: Transition time for drug chains

NEW YORK — Going forward, chain drug stores can bank on the same underlying trends that have fueled the retail pharmacy business in recent years. But the industry as they’ve known it won’t look quite the same. Retailer consolidation, changes in drug purchasing and the influx of specialty drugs are reshaping the competitive arena, industry